Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:39 PM
Ignite Modification Date:
2025-12-24 @ 11:39 PM
NCT ID:
NCT06170151
Eligibility Criteria:
Inclusion Criteria:
* patients with refractory multiple myeloma who relapsed after therapy with daratumumab in combination with dexamethasone + bortezomib or dexamethasone + lenalidomide;
* patients capable of expressing informed consent.
Exclusion Criteria:
* patients with clinical contraindications to the administration of daratumumab;
* patients with coexisting non-hematological neoplastic condition;
* patients\< 18 years;
* patients uncapable of expressing informed consent.
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06170151
Study Brief:
Protocol Section:
NCT06170151